Determination of Cremophor EL in Rat Plasma by LC-MS/MS: Application to a Pharmacokinetic Study

A rapid sensitive, and selective pseudo MRM based method for the determination of Cremophor EL (CrEL) in rat plasma was developed using Liquid chromatography/Tandem mass spectrometry (LC-MS/MS). The analytes were detected using atmospheric pressure chemical ionization (APCI) tandem mass spectrometry. Plasma concentrations of CrEL were quantified after administration through oral and intravenous routes in male sprague dawley rats at a dose of 0.26 g/kg. The standard curve was linear (0.9982) over the concentration range of 2.10 to 2100.00 μg/mL. The lower limit of quantitation for CrEL was 2.10 μg/mL using 50 μL plasma. The coefficient of variation and relative error for inter and intra assay at three QC levels were 1.23 to 8.87 and -12.08 to 4.10 respectively. CrEL has poor oral bioavailability with mean absolute bioavailability of 2.32%. CrEL plasma concentration profiles after oral and intravenous dosing were without spiky concentration levels. Spiky plasma concentration profiles for new chemical entities (NCEs) are a common phenomenon in drug discovery, which could be due to entrohepatic circulation, sample handling errors. A novel proposal was conveyed to the scientific community, where formulation vehicle can be analysed as qualifier in the analysis of NCEs to address the spiky profiles.

[1]  Ping Li,et al.  Developing early formulations: practice and perspective. , 2007, International journal of pharmaceutics.

[2]  J. Verweij,et al.  Influence of Cremophor El on the bioavailability of intraperitoneal paclitaxel. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  J. Böhler,et al.  Determination of Cremophor EL in plasma after sample preparation with solid phase extraction and plasma protein precipitation. , 2001, Journal of pharmaceutical and biomedical analysis.

[4]  A. Eschalier,et al.  Description of a short-term Taxol®-induced nociceptive neuropathy in rats , 2000, Brain Research.

[5]  J. Böhler,et al.  Titrimetric determination of Cremophor EL in aqueous solutions and biofluids: part 2: ruggedness of the method with respect to biofluids. , 1999, Journal of pharmaceutical and biomedical analysis.

[6]  M. Cotter,et al.  Effects of the diacylglycerol complexing agent, cremophor, on nerve-conduction velocity and perfusion in diabetic rats. , 1999, Journal of diabetes and its complications.

[7]  J. Verweij,et al.  Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions. , 1998, Analytical biochemistry.

[8]  J. Schneider,et al.  Analgesic effects of 1′,1′ dimethylheptyl-Δ8-THC-11-oic acid (CT3) in mice , 1998 .

[9]  H. Rosing,et al.  Influence of Cremophor EL on the quantification of paclitaxel in plasma using high-performance liquid chromatography with solid-phase extraction as sample pretreatment. , 1998, Journal of chromatography. B, Biomedical sciences and applications.

[10]  J. Verweij,et al.  Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay. , 1998, Analytical biochemistry.

[11]  J. Schneider,et al.  Analgesic effects of 1',1' dimethylheptyl-delta8-THC-11-oic acid (CT3) in mice. , 1998, Life sciences.

[12]  M. Millward,et al.  Review : Cremophor: Pharmacological activity of an "inert" solubiliser , 1997 .

[13]  J. Böhler,et al.  Separation of cremophor EL by capillary electrophoresis , 1996 .

[14]  P. Traldi,et al.  Curie-point pyrolysis-gas chromatography/mass spectrometry in the art field. 2--The characterization of proteinaceous binders. , 1996, Rapid communications in mass spectrometry : RCM.

[15]  J. Beijnen,et al.  Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography. , 1996, Journal of chromatography. B, Biomedical applications.

[16]  M. Piquet,et al.  Réactions anaphylactoïdes à une solution polyvitaminée injectable contenant un crémophore. , 1995 .

[17]  M. Luyckx,et al.  Stability, compatibility and plasticizer extraction of miconazole injection added to infusion solutions and stored in PVC containers. , 1995, Journal of pharmaceutical and biomedical analysis.

[18]  M. Piquet,et al.  [Anaphylactoid reactions to an injectable solution of a cremophor-containing solution of multivitamins]. , 1995, Therapie.

[19]  A. Windebank,et al.  Potential neurotoxicity of the solvent vehicle for cyclosporine. , 1994, The Journal of pharmacology and experimental therapeutics.

[20]  J. Boon.  Analytical pyrolysis mass spectrometry: new vistas opened by temperature-resolved in-source PYMS , 1992 .

[21]  F. Tse,et al.  Preclinical Drug Disposition: A Laboratory Handbook , 1991 .

[22]  M. Israel,et al.  Cremophor EL, a widely used parenteral vehicle, is a potent inhibitor of protein kinase C. , 1989, Biochemical and biophysical research communications.

[23]  Janssen Pa,et al.  The inhibitory effect of fentanyl and other morphine-like analgesics on the warm water induced tail withdrawl reflex in rats. , 1963 .